Declines in muscle protein synthesis account for short‐term muscle disuse atrophy in humans in the absence of increased muscle protein breakdown

Abstract

Human skeletal muscle disuse atrophy is driven by declines in MPS, not increases in MPB. Pro-anabolic therapies to mitigate disuse atrophy would likely be more effective than therapies aimed at attenuating protein degradation.